Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.10
PNHNF's Cash to Debt is ranked lower than
55% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. PNHNF: 0.10 )
PNHNF' s 10-Year Cash to Debt Range
Min: 0.05   Max: 0.56
Current: 0.1

0.05
0.56
Equity to Asset 0.12
PNHNF's Equity to Asset is ranked lower than
53% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. PNHNF: 0.12 )
PNHNF' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.56
Current: 0.12

0.12
0.56
Interest Coverage 0.71
PNHNF's Interest Coverage is ranked lower than
59% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. PNHNF: 0.71 )
PNHNF' s 10-Year Interest Coverage Range
Min: 0.17   Max: 13.77
Current: 0.71

0.17
13.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 4.87
PNHNF's Operating margin (%) is ranked higher than
75% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. PNHNF: 4.87 )
PNHNF' s 10-Year Operating margin (%) Range
Min: -4.93   Max: 12.95
Current: 4.87

-4.93
12.95
Net-margin (%) -6.72
PNHNF's Net-margin (%) is ranked higher than
64% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. PNHNF: -6.72 )
PNHNF' s 10-Year Net-margin (%) Range
Min: -42.71   Max: 6.75
Current: -6.72

-42.71
6.75
ROE (%) -52.17
PNHNF's ROE (%) is ranked higher than
55% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. PNHNF: -52.17 )
PNHNF' s 10-Year ROE (%) Range
Min: -114.92   Max: 21.15
Current: -52.17

-114.92
21.15
ROA (%) -5.50
PNHNF's ROA (%) is ranked higher than
63% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.30 vs. PNHNF: -5.50 )
PNHNF' s 10-Year ROA (%) Range
Min: -34.88   Max: 6.98
Current: -5.5

-34.88
6.98
ROC (Joel Greenblatt) (%) 6.76
PNHNF's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.19 vs. PNHNF: 6.76 )
PNHNF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7.83   Max: 17.37
Current: 6.76

-7.83
17.37
Revenue Growth (%) 13.30
PNHNF's Revenue Growth (%) is ranked higher than
89% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. PNHNF: 13.30 )
PNHNF' s 10-Year Revenue Growth (%) Range
Min: -16.8   Max: 66.3
Current: 13.3

-16.8
66.3
EBITDA Growth (%) -9.50
PNHNF's EBITDA Growth (%) is ranked higher than
63% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. PNHNF: -9.50 )
PNHNF' s 10-Year EBITDA Growth (%) Range
Min: -65.8   Max: 123.4
Current: -9.5

-65.8
123.4
EPS Growth (%) 107.80
PNHNF's EPS Growth (%) is ranked higher than
98% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. PNHNF: 107.80 )
PNHNF' s 10-Year EPS Growth (%) Range
Min: -68.9   Max: 107.8
Current: 107.8

-68.9
107.8
» PNHNF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with PNHNF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.00
PNHNF's P/B is ranked higher than
56% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.39 vs. PNHNF: 11.00 )
PNHNF' s 10-Year P/B Range
Min: 0.59   Max: 12.77
Current: 11

0.59
12.77

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 172.33
PNHNF's Price/Tangible Book is ranked higher than
56% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.63 vs. PNHNF: 172.33 )
PNHNF' s 10-Year Price/Tangible Book Range
Min: 0.75   Max: 94.33
Current: 172.33

0.75
94.33
Earnings Yield (Greenblatt) 2.30
PNHNF's Earnings Yield (Greenblatt) is ranked higher than
59% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. PNHNF: 2.30 )
PNHNF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 9.4
Current: 2.3

0.7
9.4
Forward Rate of Return (Yacktman) -1.27
PNHNF's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. PNHNF: -1.27 )
PNHNF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -30.6   Max: 22.5
Current: -1.27

-30.6
22.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PTI.Canada, PCT.Germany
Patheon Inc is a provider of commercial manufacturing outsourcing services (CMO) and outsourced pharmaceutical development services (PDS) to the pharmaceutical industry. It offers services throughout the lifecycle of a pharmaceutical molecule, from early development, through late development to commercial manufacturing, including lifecycle management services. The Company's CMO business focuses primarily on prescription products in solid and sterile dosage forms. Its PDS business provides development services, including finished dosage formulation across approximately 40 dosage forms, early development services, analytical services, formulation expertise and life cycle management. The Company competes with full-service pharmaceutical outsourcing companies; contract manufacturers focusing on a limited number of dosage forms; contract manufacturers providing multiple dosage forms; and large pharmaceutical companies, in the CMO market. It also competes with major pharmaceutical and chemical companies, specialized contract research organizations, research and development firms, universities and other research institutions, in the PDS market. The company is subject to laws and regulations concerning research and development, testing, manufacturing processes, equipment and facilities, including compliance with cGMPs, labeling and distribution, import and export, and product registration and listing.
» More Articles for PNHNF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK